IPO closes on 27 Aug'26
Symbiotec Pharmalab Limited
Minimum Investment
₹ 14,820 / 15 shares
Our Verdict:
Subscribe
- Symbiotec Pharmalab is a research-driven, vertically integrated API manufacturer with global leadership in corticosteroid and steroidal-hormone APIs and over three decades of experience; revenue grew from ₹716.25 crore (FY24) to ₹869.15 crore (FY26), a 10.16% CAGR, with EBITDA growing faster at 14.47% CAGR.
- PAT actually dipped in FY25 (₹96.79 crore, down from ₹100.06 crore in FY24) before recovering to ₹109.90 crore in FY26, and PAT margin has declined overall from 13.83% to 12.60% — growth has not been as smooth or consistent as the headline revenue and EBITDA trends suggest.
- Price Band ₹938–₹988; Issue of ₹1,757 crore (₹150 crore Fresh Issue + ₹1,607 crore Offer for Sale); Lot Size 15 shares. Anchor Aug 21, Opens Aug 24, Closes Aug 27, tentative Listing Sept 1, 2026 on BSE/NSE. GMP has risen sharply to ~₹320 (~32%) as of Aug 21, up from ₹220 just two days earlier.
- Over 91% of the issue (₹1,607 crore) is Offer for Sale — the promoter selling shareholder and two private equity investors (Rosewood Investments, India Business Excellence Fund – III) are exiting at prices far above their weighted average acquisition cost (as low as ₹49.43–₹147.21 per share) — and the post-issue P/E of ~57x is demanding against a moderate ROE of ~11% and ROCE of ~12%.
- Genuine specialised-API leadership, strong global regulatory approvals, and healthy EBITDA margins are real positives, but this is fundamentally an exit-driven listing for existing PE investors and the promoter, priced at a rich multiple relative to only moderate and somewhat inconsistent profit growth — the rising GMP suggests strong near-term demand, but the valuation leaves little cushion if growth doesn't accelerate from here.
About the company
Founded in
20 Sep'02
Managing director
Anil Satwani
- Symbiotec Pharmalab is a research-driven, vertically integrated manufacturer of active pharmaceutical ingredients (APIs), with a global leadership position in corticosteroid and steroidal-hormone APIs, built over more than three decades of industry experience.
- The Company holds approvals from the US FDA, EU-GMP and Korea's Ministry of Food and Drug Safety, among other global regulatory bodies, and operates two industrial-scale API manufacturing plants — the Rau Facility and the Pithampur Facility — with combined capacity of 584.67 MT of chemical synthesis and 300 KL of fermentation as of June 30, 2025.
- The Company is expanding into complex injectables and biotechnology products through subsidiaries including Symbiotec Zenfold Private Limited (biologics, with a Biologics Facility under construction at Ujjain) and Knovea Pharmaceutical Private Limited (Mhow Facility).
- Promoters: Anil Satwani (Chairman & Managing Director), Kashish Satwani, Sushil Satwani and Satwani Holdings LLP (Corporate Promoter); the Company is led operationally by Anil Satwani, supported by CFO Raghavender Ramachandran.
STRENGTHS
- Global Leadership in Specialised APIs: A research-driven, vertically integrated API manufacturer with a strong position in corticosteroid and steroidal-hormone APIs, backed by over three decades of industry experience.
- International Regulatory Approvals: Holds approvals from the US FDA, EU-GMP and Korea’s Ministry of Food and Drug Safety, among other global regulatory bodies, supporting access to regulated export markets.
- Revenue and EBITDA Growth: Revenue from operations grew from ₹716.25 crore (FY24) to ₹869.15 crore (FY26), a 10.16% CAGR; EBITDA grew faster, from ₹177.04 crore to ₹231.97 crore, a 14.47% CAGR.
- Vertically Integrated, Multi-Site Manufacturing: Operates two industrial-scale API manufacturing plants (Rau and Pithampur facilities) with combined capacity of 584.67 MT of chemical synthesis and 300 KL of fermentation, alongside subsidiaries developing biologics and complex injectables.
- Diversification into New Growth Segments: Expanding into complex injectables and biotechnology products through subsidiaries including Symbiotec Zenfold (biologics) and Knovea Pharmaceutical, positioning the Company beyond its core API business.
RISK FACTORS
- Extremely High Valuation: At the upper band, the issue is priced at a post-issue P/E of ~56.81x and P/B of ~5.35x on FY26 earnings, against a moderate ROE of 11.19% and ROCE of 11.56% — a demanding valuation with little room for a growth slowdown.
- Overwhelmingly OFS-Driven Structure: Of the ₹1,757 crore issue, only ₹150 crore is Fresh Issue; the remaining ₹1,607 crore (over 91%) is Offer for Sale by the promoter selling shareholder and two private equity investors (Rosewood Investments and India Business Excellence Fund – III), who acquired shares at a weighted average cost as low as ₹49.43–₹147.21, materially below the ₹938–₹988 Price Band.
- Volatile Leverage: Total borrowings swung from ₹247.21 crore (FY24) to ₹540.92 crore (FY25) before falling to ₹387.91 crore (FY26); the debt-repayment component of the issue proceeds (₹112.50 crore) addresses only part of this.
- Regulatory Dependency: The business depends on maintaining US FDA, EU-GMP and other international regulatory certifications to continue supplying regulated export markets; any lapse in these approvals could affect operations.
- Declining PAT Margin Despite Revenue Growth: PAT margin fell from 13.83% (FY24) to 12.60% (FY26), and PAT itself dipped in FY25 (₹96.79 crore) before recovering in FY26 (₹109.90 crore), a reminder that revenue growth hasn’t translated smoothly into consistent profit growth.
Financials
All Values are in Cr.
Issue details
Issue type
Mainboard
Issue size
₹ ₹1,757 crore
Fresh Issue
₹ ₹150 crore
OFS
₹ ₹1,607 crore
Price range
₹ 938 - 988
Lot size
15 shares
Issue Objective
- Net Proceeds from the Fresh Issue (₹150 crore) are proposed to be used for: (i) repayment/prepayment of certain outstanding borrowings (~₹112.50 crore); and (ii) general corporate purposes (balance amount, capped at 25% of Gross Proceeds). The Company will not receive any proceeds from the ₹1,607 crore Offer for Sale.
Dates
Bidding open
24 Aug'26
Bidding close
27 Aug'26
Allotment date
28 Aug'26
Refund date
31 Aug'26
Listing
1 Sep'26
IPO Reservations
Qualified institutional buyers
<50%
Non-institutional investors
>15%
Retail individual investors
>35%
Read the Offer Document (PDF)
© 2026 by Liquide Solutions Private Limited, SEBI Registered Research Analyst (Registration number - INH000009816)
This document has been issued by Liquide Solutions Private Limited for information purposes only. It does not have regard to specific investment objectives, financial situation and the particular needs of any specific person who may receive this document. Investors should seek personal and independent advice regarding the appropriateness of investing in any of the funds, securities, other investment or investment strategies that may have been discussed or referred herein and should understand that the views regarding future prospects may or may not be realized. In no event shall Liquide Life Private Limited and / or its affiliates or any of their directors, trustees, officers and employees be liable for any direct, indirect, special, incidental or consequential damages arising out of the use of information / opinion herein.